SLC3A2 and cancer: Moreover, treatment with Dasatinib and PF573228 abrogated the transcriptional activation of SLC7A5/SLC3A2 and SSP enzymes induced by AA restriction and enhanced the inhibitory effect of low AA on cancer cell proliferation (Fig. 5g, h).